Onset of segmental colitis associated with diverticulosis after treatment with bevacizumab for metastatic colorectal carcinoma.
Antonio
A
Tursi
D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage / Q000009:adverse effects*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D000068258:Bevacizumab; D002277:Carcinoma / Q000556:secondary* / Q000601:surgery; D003092:Colitis / Q000139:chemically induced* / Q000150:complications; D003110:Colonic Neoplasms / Q000473:pathology* / Q000601:surgery; D043963:Diverticulosis, Colonic / Q000150:complications; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D002955:Leucovorin / Q000008:administration & dosage; D008113:Liver Neoplasms / Q000188:drug therapy* / Q000556:secondary; D008297:Male; D008875:Middle Aged; D009944:Organoplatinum Compounds / Q000008:administration & dosage; D000077150:Oxaliplatin
D061067:Antibodies, Monoclonal, Humanized; D009944:Organoplatinum Compounds; D000077150:Oxaliplatin; D000068258:Bevacizumab; D002955:Leucovorin; D005472:Fluorouracil